A Clinical Practice Guideline for Ma-huang(Ephedra sinica) Prescription in Obesity

비만치료 및 체중감량에서의 적절한 마황 사용에 대한 임상 진료지침 개발

  • Kim, Ho-Jun (Dept. of Oriental Rehabilitation Medicine, Dongguk University) ;
  • Han, Chang-Ho (Dept. of Korean Internal Medicine(Cardiology), Dongguk University) ;
  • Lee, Eui-Ju (Dept of Sasang Constitutional Medicine, Kyunghee University) ;
  • Song, Yun-Kyung (Dept. of Oriental Rehabilitation Medicine, Kyungwon University) ;
  • Shin, Byung-Cheul (Dept. of Oriental Rehabilitation Medicine, Wonkwang university) ;
  • Kim, Yun-Kyung (Dept. of Herbal Medicine, College of Pharmacy, Wonkwang university)
  • 김호준 (동국대학교 한의과대학 한방재활의학과) ;
  • 한창호 (동국대학교 한의과대학 내과) ;
  • 이의주 (경희대학교 한의과대학 사상체질과) ;
  • 송윤경 (경원대학교 한의과대학 한방재활의학과) ;
  • 신병철 (원광대학교 한의과대학 한방재활의학과) ;
  • 김윤경 (원광대학교 한약학과)
  • Published : 2007.12.30

Abstract

Background Clinical practice guidelines (CPG) are systematically developed statements to assist practitioners and patients on healthcare decisions. They provide recommendations for the average patient, which should take into account individual clinical judgment and the patient's values and expectations. Ephedra has sympathomimetic effect and has been used for weight loss worldwide. However, its safety is controversial especially in autonomic and cardiovascular systems. Therefore, the need of appropriate CPG for ephedra prescription in obesity was advocated in Korean Traditional Medicine. Methods The committee comprised of specialists of obesity, oriental herbology, oriental cardiology, constitutional medicine. The committee collected all relevant references about adverse effect and safety of ephedra in the forms of meta-analysis, systematic review, randomized controlled trial, case-control study and observational study from international and domestic databases and paper journals. 11 English- and 5 Korean-language references were gathered and categorized by PICO (Patient, Intervention, Comparison, Outcome) method. We could not complete strength of recommendation which should be clarified according to the evidence grade estimation. Result The first version of CPG for ephedra prescription in obesity was issued by Korean Oriental Association for Study of Obesity. It includes topics of introduction, pharmacokinetics, side effects and adverse events, constitutional aspect and recommendations for dose, indication and contraindication. Conclusion There should be periodic upgrade of this CPG from now on. Although there are some drawbacks in this version of CPG, it has significance as the first CPG in Korean Traditional Medicine.

Keywords